Racism In School Admissions Policies

There was a time in America when schools were segregated and black children did not have the educational opportunities that white children had. Now schools are integrated, and generally opportunities are more equal. Cultural differences impact the education that children receive, but generally speaking, opportunities are equal. Some cultures put a greater emphasis on academic achievement than others, and that has become obvious to our college admissions boards and to some of our specialty high schools. Those among us who care more about equal outcome than equal opportunity have tried to change their admissions policies to compensate for those cultural differences. New York City Mayor de Blasio and Chancellor Richard Carranza have attempted to change the admissions policies for New York City’s specialized high schools.

The New York Post posted an article about the changes on March 2.

The article reports:

Last December, the Chinese American Citizens Alliance Greater New York (CACAGNY) filed a racial-discrimination lawsuit against the city after Mayor de Blasio and Chancellor Richard Carranza announced changes to admissions to New York’s specialized high schools, eight of which measure academic ability only through the SHSAT, an objective, competitive test open to every student in the city. Wai Wah Chin, the president of CACAGNY, explains why she’s determined to fight their moves, which she says discriminate against Asians …

The article reminds us of the results of this testing program:

In 1971, New York state mandated an admissions test to the city’s specialized high schools to ensure meritocratic admission. Called the SHSAT, the test knows no race or ethnicity; privilege and wealth count for nothing. All that matters is each student’s own ability.

Because of this, a Holocaust refugee who arrived in America with no English, no wealth and no privilege could take the test two years later, enter Stuyvesant and go on to win the Nobel Prize in Chemistry in 1981. His name: Roald Hoffmann.

Chancellor Carranza says no other high-school admission system in the country relies on a single test. Well, no other admission system produced 14 Nobel Prize winners in science either.

The article lists the Mayor’s solution to bringing diversity to the specialized high schools:

But de Blasio holds that meritocracy must have a predetermined, racially balanced outcome. So when East and South Asians get 50 percent of the offers to the specialized high schools while making up 16 percent of the students, he cries “Stuyvesant doesn’t look like New York City” and devises schemes to exclude them, his Asian Exclusion Act of the 21st century.

In one scheme, he arbitrarily takes 20 percent of the seats away from each Specialized High School to limit seats available to Asians. Then, he sets aside that 20 percent for students who took the SHSAT but failed to get into any of the eight schools, and applies eligibility criteria carefully crafted to exclude as many Asians as he can.

In another scheme, he brings back Harvard’s odious “geographic diversity,” limiting admission from each middle school to just 7 percent of its students, knowing full well that Asians are concentrated in a few middle schools.

These schemes impose a targeted racial balance. What’s more, they would lead to a significant portion of the student body being unprepared for the pace and levels at which the Specialized High Schools currently operate. Such social reverse engineering is the opposite of meritocracy.

If Mayor de Blasio is able to implement his ideas, it is a pretty safe bet that the number of Nobel Prize winning scientists coming out of these schools in the future will decrease drastically. I hope the CACAGNY wins their lawsuit.

Amazing News From Israel

The Jerusalem Post reported yesterday that a group of Israeli scientists believe that they have found a cure for cancer. If their clinical tests prove what they believe, this is fantastic news.

The article reports:

“We believe we will offer in a year’s time a complete cure for cancer,” said Dan Aridor, of a new treatment being developed by his company, Accelerated Evolution Biotechnologies Ltd. (AEBi), which was founded in 2000 in the ITEK incubator in the Weizmann Science Park. AEBi developed the SoAP platform, which provides functional leads to very difficult targets.

“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market,” Aridor said. “Our solution will be both generic and personal.”

…Aridor, chairman of the board of AEBi and CEO Dr. Ilan Morad, say their treatment, which they call MuTaTo (multi-target toxin) is essentially on the scale of a cancer antibiotic – a disruption technology of the highest order.

The potentially game-changing anti-cancer drug is based on SoAP technology, which belongs to the phage display group of technologies. It involves the introduction of DNA coding for a protein, such as an antibody, into a bacteriophage – a virus that infects bacteria. That protein is then displayed on the surface of the phage. Researchers can use these protein-displaying phages to screen for interactions with other proteins, DNA sequences and small molecules.

In 2018, a team of scientists won the Nobel Prize for their work on phage display in the directed evolution of new proteins – in particular, for the production of antibody therapeutics.

AEBi is doing something similar but with peptides, compounds of two or more amino acids linked in a chain. According to Morad, peptides have several advantages over antibodies, including that they are smaller, cheaper, and easier to produce and regulate.

The article concludes:

The MuTaTo cancer treatment will eventually be personalized. Each patient will provide a piece of his biopsy to the lab, which would then analyze it to know which receptors are overexpressed. The individual would then be administered exactly the molecule cocktail needed to cure his disease.
However, unlike in the case of AIDS, where patients must take the cocktail throughout their lives, in the case of MuTaTo, the cells would be killed, and the patient could likely stop treatment after only a few weeks.

The company is now writing patents on specific peptides, which will be a large bank of targeting toxin peptides wholly owned and hard to break, said Aridor.

Morad said that so far, the company has concluded its first exploratory mice experiment, which inhibited human cancer cell growth and had no effect at all on healthy mice cells, in addition to several in-vitro trials. AEBi is on the cusp of beginning a round of clinical trials which could be completed within a few years and would make the treatment available in specific cases.
Aridor added: “Our results are consistent and repeatable.”

Wow. Just wow.

Good News From The Scientific Community

Yesterday CBN News reported that the Nobel Prize for medicine has been awarded to John Gurdon from the United Kingdom and Shinya Yamanaka from Japan. The two scientists were involved in cell research.

The article reports:

Scientists John Gurdon from the United Kingdom and Shinya Yamanaka from Japan discovered it’s possible to take a cell out of an adult patient, strip-down the cell to what it was like when it was a brand new, healthy cell, then put that healthy cell into the patient in the part of the body that’s sick: such as  the brain, the spine, or heart.

The healthy cell then regenerates and takes over the sick area, making the patient well again.

The technique has proved successful with heart patients in a study at the University of Louisville.

The cells that the scientists used were adult stem cells, not embryonic stems cells.

The article further reports:

“It’s not hype, it is really hope. I think that stem cells will likely become a routine part of the treatment of cardiovascular disease in the next  few years,” Dr. Bolli said.

The discovery is good news for those who believe in the sanctity of life. Until now, much of the scientific community believed this type of cell regeneration needs to start with living, human embyos, a process that destroys the embryo.

This research will allow stem cell research to continue without creating life in order to destroy it. Adult stem cells have generally proven to be more successful in helping cure certain diseases than embryonic stem cells. This is a win for patients and for those who believe that life should not be created for the purpose of being destroyed.

Enhanced by Zemanta